0.0012  0 (0%)		06-12 16:00
Open: 0.0398 High: 0.0398 Volume: 800		Pre. Close: 0.0012 Low: 0.0012 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Pressure BioSciences, Inc. (PBI) provides cutting-edge pressure-driven platform solutions to markets across North America, Europe, and Asia. At its core is the proprietary Pressure Cycling Technology (PCT), which utilizes alternating hydrostatic pressure, oscillating between ambient and exceedingly high levels, to precisely regulate molecular processes within various biological specimens. These specimens include cells and tissues originating from human, animal, plant, and microbial organisms. PBI's instrumentation portfolio features a suite of Barocycler devices, such as the 2320EXT, HUB880, HUB440, and The Shredder SG3. Beyond its primary instruments, the firm also supplies cell disruption apparatus, associated components, and expendable items. Furthermore, PBI provides Barocycler-compatible consumables, including PCT MicroTubes, PCT MicroCaps, the PCT-Micro Pestle, and specialized pressure lysis tubes, alongside comprehensive application-specific kits that bundle necessary consumables and reagents. Its clientele encompasses researchers within academic institutions, governmental bodies, biotechnology enterprises, pharmaceutical corporations, and other life science organizations. PBI actively collaborates with esteemed partners such as RedShiftBio Inc., Inova Schar Cancer Center, NYU, Leica Microsystems, GmbH, the Steinbeis Centre for biopolymer analysis and biological mass spectrometry, The Ohio State University, the University of Delaware, and Cedars Sinai Medical Center. Originally established in 1978 as Boston Biomedica, Inc., the company is headquartered in South Easton, Massachusetts. Effective August 2, 2022, Pressure BioSciences, Inc. began operating as a subsidiary of Emergent Health Corp.

Fri, 07 Feb 2025
Pressure Biosciences Inc. (PBIO) reports earnings - qz.com

Mon, 22 Jan 2024
Pressure BioSciences Announces Closing of Uncle Bud’s Acquisition in All-Stock Transaction, Completing UltraShear Nanoemulsions Forward Integration with World Class Marketing & Sales - Yahoo Finance

Thu, 11 Jan 2024
Pressure BioSciences Signs Definitive Agreement to Acquire Uncle Bud’s, Forward Integrating PBIO’s UltraShear Platform into Multiple Markets - Business Wire

Wed, 07 Dec 2022
Pressure BioSciences Partnership with QVC Skincare Leader Dr. Denese SkinScience Yields Unprecedented Effectiveness in Skin Tightening and Wrinkle Reduction - Yahoo Finance

Sat, 19 Nov 2022
Daniel Joseph Shea Net Worth (2026) - GuruFocus

Fri, 25 Jun 2021
Shear technology uses homogenization and ultrahigh pressure to improve quality, kill bacteria - foodengineeringmag.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: OTC
Sector: Healthcare
Industry: Medical - Devices
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date